YAP1 and hepatocellular carcinoma: Furthermore, talazoparib, a novel and potent poly(ADP-ribose)polymerase-1/2 (PARP1/2) inhibitor, induces the lncRNA PLK4, which inhibits the viability and growth of HCC cells through YAP inactivation and cellular senescence, thus acting as an oncogene suppressor (54).